A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors. Posted byadmin 28. July 2020 Dittrich, C, Fridrik, MA, Koenigsberg, R, Lee, C, Goeldner, R, Hilbert, J, Greil, R. http://www.ncbi.nlm.nih.gov/pubmed/25529193